GlobeNewswire 32497 posts 0 comments

If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most…

Revenue growth +20.2%Organic revenue growth +12.3% Issy-les-Moulineaux, January 6, 2023 Sodexo (NYSE Euronext Paris FR…

Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of…

New ’Mobilisights’ Business Unit Advances Stellantis’ Growing Data and Connected Services Offer Mobilisights will leverage data…

Toronto, ON, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Canada Carbon Inc. (the “Company”) (TSX-V:CCB), (FF:U7N1) reports that it…

Phoenix, AZ, Jan. 05, 2023 (GLOBE NEWSWIRE) -- On January 5, 2023, the Board of Trustees of InnSuites Hospitality Trust (NYSE Am:…

Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60% BOCA RATON,…

Cayman Islands, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AlphaTime Acquisition Corp (NASDAQ: ATMCU, the “Company”), a newly organized…

CHICAGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading…

Hemostat Market Size By Product (Thrombin-Based Hemostats, Oxidized Regenerated Cellulose-Based Hemostats, Collagen-Based…